Download or read book Real-world Treatment Experience in Patients with Ovarian Cancer: Findings from a Retrospective Analysis of the SEER-Medicare Database in the United States written by Gboyega Adeboyeje and published by . This book was released on 2017 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: Background:Despite high response rates to initial treatment, high recurrence rates remain a persistent challenge among patients with ovarian cancer (OC). There is limited data on overall survival (OS) rates and burden of disease in terms of resource use with contemporary standard of care. We examined the treatment experience of real-world patients in the United States (U.S) at 1-, 2-, 3- and 4-year landmarks.Methods:Using a single-arm retrospective cohort study design, we identified OC patients from the Surveillance, Epidemiology and End Results (SEER)-Medicare database who were aged u226566 years and had completed 4 u2013 10 cycles of platinum-based first-line (1L) chemotherapy from January 2009 to December 2015. The descriptive outcomes were OS, rates of hospitalization, mean number of hospitalizations and length of hospital stay (LOS), receipt of bevacizumab and proportion of patients who initiated non-platinum therapies, and transition rates through lines of therapy at 1-, 2-, 3- and 4-year landmarks.Results:We identified a total of 2,262 patients (mean age was 74.6 u00b16.2 years). 29.9% of patients had u22651 non-cancer comorbidity. 90.2% of patients were white.At 1 year after initiating chemotherapy, 90.7% of patients were alive, 56.1% were hospitalized at least once with a mean LOS of 16 days; 10.2% had received bevacizumab and 20.5% had initiated a nonplatinum-based therapy. At 4 years, 44.1% of patients were alive, 72.6% were hospitalized at least once with a mean LOS of 22 days; 31% had received bevacizumab and 56.2% had initiated a nonplatinum-based therapy. The proportion of patients who had died, completed or were receiving 3 or more lines of therapy increased from 10.1% at 1 year to 74.2% at 4 years from initiating chemotherapy. Among 1,538 patients with known treatment or mortality status after 4 years post-treatment initiation.Conclusions:The increasing burden of therapy and hospitalizations over time demonstrate the need for more effective front-line therapies to delay progression in ovarian cancer. Less than a fifth of OC patients received no further treatment 4 years after the initial treatment with contemporary standard of care.